ELUTIA INC
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
ELUT$0.93+11.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In Thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · March 31, | ||||||
| · · 2024 · 2023 | ||||||
| Net loss | | $(17,994) | $(7,974) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | |||||
| Depreciation and amortization | | 864 | 947 | |||
| Loss on revaluation of warrant liability | | 9,637 | — | |||
| Gain on revaluation of revenue interest obligation | | (1,443) | — | |||
| Amortization of deferred financing costs and debt discount | | 54 | 53 | |||
| Interest expense recorded as additional revenue interest obligation and long-term debt | | 781 | 796 | |||
| Stock-based compensation | | 2,197 | 684 | |||
| Changes in operating assets and liabilities: | | | | |||
| Accounts receivable | | (1,143) | (504) | |||
| Inventory | | 801 | (1,003) | |||
| Receivables of litigation costs | | | 665 | | | 2,892 |
| Prepaid expenses and other | | 168 | 648 | |||
| Accounts payable and accrued expenses and payables to tissue suppliers | | 2,026 | (56) | |||
| Contingent liability for FiberCel litigation | | | 567 | | | (1,729) |
| Other liabilities | | 179 | 80 | |||
| Net cash used in operating activities | | (2,641) | (5,166) | |||
| INVESTING ACTIVITIES: | | | ||||
| Expenditures for property, plant and equipment | | (15) | (182) | |||
| Net cash used in investing activities | | (15) | (182) | |||
| FINANCING ACTIVITIES: | | |||||
| Repayments of long-term debt | | (2,000) | — | |||
| Proceeds from exercises of Common Warrants and Prefunded Warrants | | | 1,140 | | | — |
| Payments on revenue interest obligation | | (2,600) | — | |||
| Repayments of insurance premium financings | | | (673) | | | — |
| Payments for taxes upon vesting of restricted stock units | | | (6) | | | — |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | | 70 | 148 | |||
| Net cash provided by (used in) financing activities | | (4,069) | 148 | |||
| | | | | | | |
| Net decrease in cash and restricted cash | | (6,725) | (5,200) | |||
| | | | | | | |
| Cash, beginning of period | | 19,276 | 16,989 | |||
| Cash, end of period | | $12,551 | $11,789 | |||
| | | | | | | |
| Supplemental Cash Flow and Non-Cash Financing Activities Disclosures: | | |||||
| Cash paid for interest | | $2,541 | $572 | |||
| Conversion of Common Warrants and Prefunded Warrants to common stock | | $2,894 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.